

# Dry Age-Related Macular Degeneration: Distribution of Visual Acuity and Progression Risk in a Large Registry

Theodore Leng, MD, MS, Jason Schwartz, MD, David Nimke, DrPH, MPH, Mark Gallivan, MPH, Helene Fevrier, MPSH, Nigel Rozario, PhD, Neil M. Schultz, PharmD, MS

## Patients and Methods



### Study Design

Retrospective observational cohort



### Inclusion Criteria

dAMD in  $\geq 1$  eye, subsequent visit documented in registry, and  $\geq 1$  VA measurement



### Data

AAO IRIS<sup>®</sup> Registry



### Models

Developed to estimate VA and risk of worsening VA across dAMD stage

## Results



Data from **593,277** patients were analyzed

## Key Messages

**Real-world results** complement those from randomized trials



Patients with more advanced dAMD **have lower VA at baseline**



**VA progression is generally faster** with each progressive dAMD stage



**VA worsening was greater** among eyes with better VA at baseline



**Abbreviations:** AAO, American Academy of Ophthalmology; dAMD, dry age-related macular degeneration; IRIS, Intelligent Research in Sight; VA, visual acuity